Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2025
Date of Filing: July 30, 2025
This filing reports the issuance of a press release regarding a clinical trial milestone for the company's lead candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific corporate event and does not contain financial statements.
Material Changes
Clinical Development Milestone: Can-Fite Biopharma Ltd. announced that its Phase 2a study for Namodenoson in pancreatic cancer has achieved an enrollment milestone of over 50%.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses solely on the progress of the pancreatic cancer study. No specific financial guidance, future outlook, or discussion of risks and contingencies is included in this specific Form 6-K text.
Investor Verification Checklist
- Verify the full details of the Namodenoson Phase 2a study design and patient population in the attached press release (Exhibit 99.1).
- Review the company's most recent Form 20-F or quarterly report for current cash runway and burn rate, as this filing contains no financial data.
- Monitor upcoming updates regarding the remaining 50% of the study enrollment and subsequent data readout timelines.